Last reviewed · How we verify

Diagnostic aid — Treatment Landscape & Competitive Intelligence

Diagnostic aid (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diagnostic aid, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lymphoseek Kit TECHNETIUM TC 99M TILMANOCEPT Navidea Biopharms Radioactive Diagnostic Agent 2013-01-01
Sincalide SINCALIDE Bracco Cholecystokinin Analog [EPC] Cholecystokinin receptor type A 1976-01-01
Ipodate iopodic acid Bracco iopodic acid 1962-01-01
Lymphoseek Lymphoseek Eben Rosenthal

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Diagnostic aid
  2. Bracco · 2 drugs in Diagnostic aid
  3. Eben Rosenthal · 1 drug in Diagnostic aid
  4. Navidea Biopharms · 1 drug in Diagnostic aid

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diagnostic aid:

Cite this brief

Drug Landscape (2026). Diagnostic aid — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diagnostic-aid. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing